Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)

The Lancet Oncology · Published 2026-07-03 · DOI 10.1016/s1470-2045(26)00145-2

Authors (36)

Christophe M. Deroose, Hannes Leupe, Rodney J Hicks, Irene Virgolini, Arthur J A T Braat, Erik S Mittra, Nathalie L Albert, Dale L Bailey, Lisa Bodei, David L Chan, Jeroen Dekervel, Timm Denecke, Clarisse Dromain, Massimo Falconi, Laure Fournier, Simona Grozinsky-Glasberg, Johannes Hofland, Thomas A Hope, Ioannis Karfis, Beata Kos-Kudła, Anna Koumarianou, Angela Lamarca, Saskia Litière, Marianne Pavel, Sigrid Stroobants, Jonathan Strosberg, Anders Sundin, David Taïeb, Nikolaos Trikalinos, Marcus Unterrainer, Chris Verslype, Namrata Vijayvergia, Damian Wild, Andreas Kjaer, Valentina Ambrosini, Vikas Prasad

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Deroose, C., Leupe, H., Hicks, R., et al. (2026). Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS). The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00145-2

Related articles